Comparing 6 Months Versus 12 Months of Immunotherapy After Surgery for High-Risk Stage IIb-c, III, and IV Cutaneous Malignant Melanoma
Led by Uppsala University · Updated on 2026-03-09
1792
Participants Needed
26
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether a shorter period of immunotherapy after radical surgery is as effective as the standard longer treatment for patients with high-risk malignant skin melanoma. This study focuses on people aged 18 and older who have undergone surgery for stage IIb-c, III, or IV melanoma. The goal is to see if six months of immunotherapy can prevent cancer recurrence as well as the current 12-month treatment, potentially reducing side effects, hospital visits, and healthcare costs. The study is a randomized phase 3 trial conducted internationally with patients followed for up to five years.
Participants will receive immunotherapy drugs, currently nivolumab or pembrolizumab, given intravenously. They are randomly assigned to either six months experimental group or 12 months standard group of treatment. Patients who had immunotherapy before surgery neoadjuvant treatment can also join, with their pre-surgery treatment time added to the post-surgery treatment. Medical exams and imaging scans CT or PET-CT are done at the start, six months, and 36 months, along with regular check-ups over three years. If cancer returns, additional tests and treatments are planned based on medical team decisions.
During the study, participants will have scheduled visits for physical exams, blood tests, and scans to monitor their health and detect any recurrence. Researchers will measure relapse-free survival and distant metastatic-free survival at two years as primary outcomes, with overall survival and health economic effects also assessed over five years. Safety monitoring includes standard care practices and follow-up for up to five years. The study aims to confirm if shorter immunotherapy duration maintains the same outcomes while benefiting patients and healthcare systems.
CONDITIONS
Brief Title
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Research Team
G
Gustav J Ullenhag, professor
L
Leila Boukharta, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Have undergone radical surgery for stage IIb-c, III (including in transit), or IV cutaneous malignant melanoma
Stage III patients with unknown primary and stage IIb-c patients without sentinel node procedure are eligible
Complete physical exam within 28 days before randomization
Previous adjuvant treatment with BRAF + MEK inhibitors is allowed
Neoadjuvant immunotherapy for two months allowed if complete or near complete pathological response was not achieved
Disease-free status documented by radiology within 28 days before randomization (6 weeks if neoadjuvant treated)
Off systemic immunosuppressive steroids (>10 mg/day prednisone or equivalent) for at least 14 days before treatment
Sufficient kidney function for radiological contrast assessments
Peri-operative radiation therapy allowed
Patients with locoregional lymph node relapse or operable stage IV at later time points are eligible
You will not qualify if you...
Assessed as unfit for systemic adjuvant treatment by investigator
Serious or uncontrolled medical disorder contraindicating treatment
Active, known, or suspected autoimmune disease (except type I diabetes, hypothyroidism needing hormone replacement, or certain skin disorders not requiring systemic treatment)
Life expectancy less than 2 years due to other diseases
Unable or unwilling to provide informed consent
Unable to follow study protocol
Participation in other clinical trials interfering with this study
Other malignancies within past 5 years except certain low-risk cancers
Pregnancy or planned pregnancy
Ocular or mucosal melanoma
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 baseline visit (in-person) for study information, inclusion, and randomization
Treatment
Duration - 6 or 12 months
Participants receive adjuvant immunotherapy with PD-1 inhibitors following radical surgery for high-risk malignant melanoma. Treatment duration is either 6 months or 12 months depending on randomization.
Regular visits for treatment administration and side effect management based on national guidelines
Follow-up
Duration - Up to 5 years
Participants undergo follow-up visits with imaging and physical examinations according to national routine schedules to monitor for disease recurrence and manage health after treatment completion.
Follow-up visits including CT or FDG-PET-CT scans at baseline, 6 months, and 36 months, plus regular doctor appointments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá...
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.
Patric Ejder, Henrik Jespersen, Micaela Hernberg...